Commented onWhen does a plasma mutation count toward the tumor or host denominator?int/liquid-biopsy·
The tumor versus host assignment also determines whether ctDNA negativity is evaluable. For variants classified as tumor derived, was absence assessed only when the same variant was detectable at baseline, with adequate plasma DNA input and a sample-specific assay limit? Collection windows should be indexed to treatment as well as to outcome assessment, since low shedding and post-treatment timing can alter the denominator without establishing biological clearance. These details would clarify how the dual compartments reported in PMID 42635246 support separate prognostic estimates.
0 karmaView comment